MOBILE VIEW  | 

ANTIPERSPIRANTS

Classification   |    Detailed evidence-based information

Therapeutic Toxic Class

    A) Antiperspirants are agents which are intended to reduce sweating.

Specific Substances

    A) anhydrous aluminum chloride
    1) CAS 7446-70-0
    aluminum chloride hexahydrate
    1) CAS 7784-13-6
    anhydrous aluminum sulfate
    1) CAS 10043-01-3
    aluminum sulfate hydrate
    1) CAS 17927-65-0
    GENERAL TERM
    1) Antiperspirant

Available Forms Sources

    A) FORMS
    1) Over-the-counter (OTC) products contain:
    a) ALUMINUM CHLORIDE: In water, aluminum chloride produces aluminum hydroxide plus hydrochloric acid, making a strongly acidic solution. 15% is the maximum concentration allowed for an over-the-counter product. Aluminum chloride is irritating to skin, may damage clothes, but has the best efficacy (Shelley & Hurley, 1980).
    1) Prescription products are available with stronger (higher) levels of aluminum chloride including:
    a) 20% aluminum chloride hexahydrate in alcohol.
    b) 6.25% aluminum chloride hexahydrate in anhydrous ethanol.
    b) ALUMINUM CHLOROHYDRATES: There are several formulas with different concentrations of aluminum and chloride. The two most commonly used are Al2(OH)4Cl2(2/3 basic aluminum chloride) and Al2 (OH)5 Cl (which is 5/6 basic aluminum chloride). Aluminum chloride is also available in PEG or propylene glycol complexes to increase its solubility. The maximum allowable concentration for over-the-counter products is 25%. These agents have little skin irritation. A 20% solution in water has a pH of 4.4. Most aerosols are aluminum chlorohydrate and are anhydrous (Emery, 1987).
    c) ZIRCONIUM SALTS: These were used in over-the-counter products until they were found to produce skin and lung granulomas. Aerosol products have been banned.
    d) ALUMINUM-ZIRCONIUM CHLOROHYDRATES: These are safer than zirconium alone, but rabbits injected with aluminum zirconium-glycine compounds did have skin changes. This substance has a pH of approximately 4 in solution. They can be used topically only in the maximum concentration of 20% (Anon, 1977b). They are weaker acids than aluminum chloride, and have lower irritation potential and cause less damage to clothing (Emery, 1987).
    e) BUFFERED ALUMINUM SULFATE: This is available as an 8% solution buffered by 8% sodium aluminum lactate. This is an effective agent and virtually nonirritating.
    f) GLUTARALDEHYDE: This agent is usually used in a 2% buffered solution, but only on soles and palms, not axillae.
    2) Antiperspirants are designated as "over-the-counter" drug products by the FDA, and are labeled for active ingredient and vehicular composition listed in the order of predominance in the product (Emery, 1987).
    B) USES
    1) Antiperspirants are agents which are intended to reduce sweating.
    2) Aluminum chloride has been used for treatment of chronic folliculitis due to both its antibacterial and antiperspirant activity (Shelley & Hurley, 1980).

Life Support

    A) This overview assumes that basic life support measures have been instituted.

Clinical Effects

    0.2.1) SUMMARY OF EXPOSURE
    A) USES: Antiperspirants are used topically to reduce perspiration and control body odor.
    B) PHARMACOLOGY: Not fully understood; proposed mechanisms included astringent effect, increasing permeability of sweat duct, and mechanical plugging of ducts.
    C) TOXICOLOGY: Toxicity is due to irritant effects.
    D) EPIDEMIOLOGY: Widely used but toxic exposure is rare.
    E) WITH POISONING/EXPOSURE
    1) MILD TO MODERATE: Skin and eye irritation can occur after topical or eye exposure; contact dermatitis has been reported. GI irritation can occur after ingestion. Respiratory irritation and cough can occur after inhalation of aerosols.
    2) SEVERE: Severe toxicity has not been reported.

Laboratory Monitoring

    A) No laboratory measures are necessary with these ingestions.

Treatment Overview

    0.4.2) ORAL/PARENTERAL EXPOSURE
    A) MANAGEMENT OF TOXICITY
    1) Systemic symptoms are unlikely. Supportive care for mild irritant symptoms is all that is necessary.
    B) DECONTAMINATION
    1) Acute toxicity is limited; GI decontamination is not indicated. Wash skin and irrigate eyes. Dilution with small amounts of water may help with GI irritant effects.
    C) PATIENT DISPOSITION
    1) HOME CRITERIA: Patients with minimal irritant symptoms after inadvertent exposure can be managed at home.
    2) OBSERVATION CRITERIA: Patients with deliberate self harm exposures or persistent symptoms should be sent to a healthcare facility for evaluation.
    D) PITFALLS
    1) Acute toxicity is not significant; do not overtreat.
    E) PHARMACOKINETICS
    1) There is little absorption after dermal application.
    F) DIFFERENTIAL DIAGNOSIS
    1) Exposure to other irritants.
    0.4.4) EYE EXPOSURE
    A) DECONTAMINATION: Remove contact lenses and irrigate exposed eyes with copious amounts of room temperature 0.9% saline or water for at least 15 minutes. If irritation, pain, swelling, lacrimation, or photophobia persist after 15 minutes of irrigation, the patient should be seen in a healthcare facility.
    0.4.5) DERMAL EXPOSURE
    A) OVERVIEW
    1) DECONTAMINATION: Remove contaminated clothing and jewelry and place them in plastic bags. Wash exposed areas with soap and water for 10 to 15 minutes with gentle sponging to avoid skin breakdown. A physician may need to examine the area if irritation or pain persists (Burgess et al, 1999).

Range Of Toxicity

    A) TOXICITY: Poisoning by aluminum salts is unlikely. Most of the other ingredients (except alcohol) are in such low concentrations that toxicity is unlikely. In many cases, the toxic dose exceeds the package size.
    B) An adult developed bone pain and extreme fatigue associated with elevated aluminum concentrations after applying 1 g of an aluminum chlorohydrate-containing antiperspirant cream on each underarm every morning for 4 years.

Summary Of Exposure

    A) USES: Antiperspirants are used topically to reduce perspiration and control body odor.
    B) PHARMACOLOGY: Not fully understood; proposed mechanisms included astringent effect, increasing permeability of sweat duct, and mechanical plugging of ducts.
    C) TOXICOLOGY: Toxicity is due to irritant effects.
    D) EPIDEMIOLOGY: Widely used but toxic exposure is rare.
    E) WITH POISONING/EXPOSURE
    1) MILD TO MODERATE: Skin and eye irritation can occur after topical or eye exposure; contact dermatitis has been reported. GI irritation can occur after ingestion. Respiratory irritation and cough can occur after inhalation of aerosols.
    2) SEVERE: Severe toxicity has not been reported.

Heent

    3.4.3) EYES
    A) WITH POISONING/EXPOSURE
    1) CORNEAL EPITHELIAL DAMAGE: The aluminum chloride salt used in antiperspirants is aluminum chloride hexahydrate which is not as acidic or caustic as anhydrous aluminum chloride. Antiperspirants accidentally contacting the eyes sometimes cause slight transient disturbances of the corneal epithelium, but no serious or persistent injury has been reported.
    a) Aluminum chloride hexahydrate was tested under extreme conditions by applying 100 mg of crystals to the cornea of a rabbit after applying a local anesthetic eye drop, and it was found that this caused immediate blepharospasm as from pain, despite the local anesthetic. If the crystals were allowed to remain until tears washed them away, they caused transient epithelial damage and a persistent, faint nebula in the corneal stroma (Grant & Schuman, 1993).

Respiratory

    3.6.2) CLINICAL EFFECTS
    A) COUGH
    1) Inhalation of aerosol antiperspirants may cause temporary cough, but no serious sequelae are expected.

Neurologic

    3.7.2) CLINICAL EFFECTS
    A) CENTRAL NERVOUS SYSTEM FINDING
    1) Although the antiperspirant aluminum salts are not expected to produce neurologic symptoms, additives, such as ethanol or essential oils, may cause CNS depression or stimulation (ie, seizures) if large quantities have been ingested.
    B) ALZHEIMER'S DISEASE
    1) CASE SERIES: A controlled study of 130 matched pairs of patients found no significant correlation between lifetime use of aluminum-containing antiperspirants and Alzheimer's disease (Graves et al, 1990).
    C) FATIGUE
    1) WITH POISONING/EXPOSURE
    a) CASE REPORT: A 43-year-old woman developed bone pain and extreme fatigue after applying 1 g of an aluminum chlorohydrate-containing antiperspirant cream on each underarm every morning for 4 years. It was found that 1 g of the cream contained 20% aluminum chlorohydrate providing a dose of 0.108 g of aluminum(III) per day and a dose of 157.3 g over a 4-year period. Aluminum levels in plasma and urine were 3.88 mcmol/L (10.47 mcg/dL) and 1.71 mcmol/24 hours (46.1 mcg/24 hours) with normal being less than 1.1 mcmol/24 hours or 29.7 mcg/24 hours), respectively. Eight months after the discontinuation of the antiperspirant, she recovered completely without further sequelae (Guillard et al, 2004).

Gastrointestinal

    3.8.2) CLINICAL EFFECTS
    A) GASTROINTESTINAL IRRITATION
    1) Gastrointestinal (GI) reactions vary by the constituents of the antiperspirant. The aluminum salts used are not caustic and will generally cause only mild to moderate GI irritation.
    B) VOMITING
    1) Some of the more concentrated aluminum chloride products are in alcoholic solutions. Thus, the alcohol may cause vomiting or mild CNS depression if the amount ingested is significant.
    C) DIARRHEA
    1) Some of the product bases may contain waxes, glycine and glycerol, fatty acids, and oils which may cause diarrhea when taken in large amounts.

Dermatologic

    3.14.2) CLINICAL EFFECTS
    A) SKIN IRRITATION
    1) These products may be irritating to the skin, producing a burning sensation, tingling, or mild rashes or papules. Skin burns are not anticipated, and allergies are infrequent.
    2) CASE SERIES: Four of 12 patients treated with an aluminum chloride hexahydrate antiperspirant developed a stinging sensation immediately after application. The symptom disappeared in 3 patients after 1 week despite continuation of treatment (Goh, 1990).
    3) When applied to damp skin, aluminum chloride-containing antiperspirants may be particularly irritating due to the formation of hydrochloric acid (Sweetman, 2003).
    B) CONTACT DERMATITIS
    1) CASE SERIES: In a study of 982 women who regularly used cosmetics, antiperspirants, deodorants, and personal cleanliness products, only 2% tested positive on patch tests for contact allergy to components of these products while 25% complained of irritation (DeGroot et al, 1988).
    2) Chlorphenesin is an antifungal used in antiperspirant/deodorant products. One case of positive patch tests and contact dermatitis due to this ingredient has been reported (Goh, 1987).
    3) CASE SERIES: A study of 19 male soldiers was conducted to determine the efficacy of antiperspirants in reducing foot sweat accumulation and injuries. Twelve soldiers (38%) developed irritant dermatitis as a result of application of the antiperspirants to the feet. It is speculated that the dermatitis could be due to the aluminum component in the antiperspirant (Darrigrand et al, 1992).
    C) GRANULOMA
    1) CASE REPORT: A 27-year-old female developed an acutely inflamed right axillary mass following several years of aluminum-zirconium complex-containing antiperspirant use. A histologic examination revealed granulomatous inflammation. The granuloma disappeared after discontinuation of the antiperspirant (Skelton et al, 1993).

Musculoskeletal

    3.15.2) CLINICAL EFFECTS
    A) BONE PAIN
    1) WITH POISONING/EXPOSURE
    a) CASE REPORT: A 43-year-old woman developed bone pain and extreme fatigue after applying 1 g of an aluminum chlorohydrate-containing antiperspirant cream on each underarm every morning for 4 years. It was found that 1 g of the cream contained 20% aluminum chlorohydrate providing a dose of 0.108 g of aluminum(III) per day and a dose of 157.3 g over a 4-year period. Aluminum levels in plasma and urine were 3.88 mcmol/L (10.47 mcg/dL) and 1.71 mcmol/24 hours (46.1 mcg/24 hours) with normal being less than 1.1 mcmol/24 hours or 29.7 mcg/24 hours, respectively. Eight months after the discontinuation of the antiperspirant, she recovered completely without further sequelae (Guillard et al, 2004).

Monitoring Parameters Levels

    4.1.1) SUMMARY
    A) No laboratory measures are necessary with these ingestions.

Life Support

    A) Support respiratory and cardiovascular function.

Patient Disposition

    6.3.1) DISPOSITION/ORAL EXPOSURE
    6.3.1.2) HOME CRITERIA/ORAL
    A) Patients with minimal irritant symptoms after inadvertent exposure can be managed at home.
    6.3.1.5) OBSERVATION CRITERIA/ORAL
    A) Patients with deliberate self harm exposures or persistent symptoms should be sent to a healthcare facility for evaluation.

Monitoring

    A) No laboratory measures are necessary with these ingestions.

Oral Exposure

    6.5.1) PREVENTION OF ABSORPTION/PREHOSPITAL
    A) Acute toxicity is limited; GI decontamination is not indicated. Wash skin and irrigate eyes. Dilution with small amounts of water may help with GI irritant effects.
    6.5.2) PREVENTION OF ABSORPTION
    A) Acute toxicity is limited; GI decontamination is not indicated. Wash skin and irrigate eyes. Dilution with small amounts of water may help with GI irritant effects.
    6.5.3) TREATMENT
    A) SUPPORT
    1) Systemic symptoms are unlikely. Supportive care for mild irritant symptoms is all that is necessary.
    B) MONITORING OF PATIENT
    1) No laboratory measures are necessary with these ingestions.
    C) DILUTION
    1) DILUTION: If no respiratory compromise is present, administer milk or water as soon as possible after ingestion. Dilution may only be helpful if performed in the first seconds to minutes after ingestion. The ideal amount is unknown; no more than 8 ounces (240 mL) in adults and 4 ounces (120 mL) in children is recommended to minimize the risk of vomiting (Caravati, 2004).

Eye Exposure

    6.8.1) DECONTAMINATION
    A) EYE IRRIGATION, ROUTINE: Remove contact lenses and irrigate exposed eyes with copious amounts of room temperature 0.9% saline or water for at least 15 minutes. If irritation, pain, swelling, lacrimation, or photophobia persist after 15 minutes of irrigation, an ophthalmologic examination should be performed (Peate, 2007; Naradzay & Barish, 2006).

Dermal Exposure

    6.9.1) DECONTAMINATION
    A) DERMAL DECONTAMINATION
    1) DECONTAMINATION: Remove contaminated clothing and wash exposed area thoroughly with soap and water for 10 to 15 minutes. A physician may need to examine the area if irritation or pain persists (Burgess et al, 1999).
    6.9.2) TREATMENT
    A) IRRITATION SYMPTOM
    1) Skin irritation due to antiperspirant use can usually be controlled by discontinuation of the product.
    B) Treatment should include recommendations listed in the ORAL EXPOSURE section when appropriate.

Summary

    A) TOXICITY: Poisoning by aluminum salts is unlikely. Most of the other ingredients (except alcohol) are in such low concentrations that toxicity is unlikely. In many cases, the toxic dose exceeds the package size.
    B) An adult developed bone pain and extreme fatigue associated with elevated aluminum concentrations after applying 1 g of an aluminum chlorohydrate-containing antiperspirant cream on each underarm every morning for 4 years.

Therapeutic Dose

    7.2.1) ADULT
    A) GENERAL
    1) For the treatment of hyperhidrosis, an antiperspirant containing aluminum chloride in a 20% alcoholic solution is applied to dry skin at bedtime and is washed off in the morning before the sweat glands are completely active (Sweetman, 2001).

Maximum Tolerated Exposure

    A) GENERAL/SUMMARY
    1) Poisoning by aluminum salts is unlikely. Most of the other ingredients (except alcohol) are in such low concentrations that toxicity is unlikely. In many cases, the toxic dose exceeds the package size.
    2) CASE REPORT: A 43-year-old woman developed bone pain and extreme fatigue after applying 1 g of an aluminum chlorohydrate-containing antiperspirant cream on each underarm every morning for 4 years. It was found that 1 g of the cream contained 20% aluminum chlorohydrate providing a dose of 0.108 g of aluminum(III) per day and a dose of 157.3 g over a 4-year period. Aluminum levels in plasma and urine were 3.88 mcmol/L (10.47 mcg/dL) and 1.71 mcmol/24 hours (46.1 mcg/24 hours) with normal being less than 1.1 mcmol/24 hours or 29.7 mcg/24 hours, respectively. Eight months after the discontinuation of the antiperspirant, she recovered completely without further sequelae (Guillard et al, 2004).

Toxicity Information

    7.7.1) TOXICITY VALUES
    A) ALUMINUM CHLORIDE
    1) LD50- (ORAL)MOUSE:
    a) 1130 mg/kg (RTECS , 2001)
    2) LD50- (ORAL)RAT:
    a) 3450 mg/kg (RTECS , 2001)

Pharmacologic Mechanism

    A) The exact mechanism of action is unknown for antiperspirants. Some of the proposals are:
    1) Simple astringency, which decreases pore size.
    2) An increase in permeability of the sweat duct (leaky hose).
    3) Plugging the pores with keratin or an amorphus aluminum containing cast that extends down the duct. A high degree of acidity is necessary for this action (Anon, 1982).

General Bibliography

    1) Anon: Aerosol drug and cosmetic products containing zirconium. Federal Register 1977b; 42:11371-11376.
    2) Anon: Personal Care Products in Handbook of Nonprescription Drugs, 7th ed, American Pharmaceutical Assoc, Washington, DC, 1982.
    3) Burgess JL, Kirk M, Borron SW, et al: Emergency department hazardous materials protocol for contaminated patients. Ann Emerg Med 1999; 34(2):205-212.
    4) Caravati EM: Alkali. In: Dart RC, ed. Medical Toxicology, Lippincott Williams & Wilkins, Philadelphia, PA, 2004.
    5) Darrigrand A, Reynolds K, & Jackson R: Efficacy of antiperspirants on feet. Military Med 1992; 157:256-259.
    6) DeGroot AC, Beverdam GA, & Ayong CT: The role of contact allergy in the spectrum of adverse effects caused by cosmetics and toiletries. Contact Dermatitis 1988; 19:195-201.
    7) Emery IK: Antiperspirants and deodorants. Cutis 1987; 39:531-532.
    8) Goh CL: Aluminum chloride hexahydrate versus palmar hyperhidrosis. Intl J Dermatol 1990; 29:368-370.
    9) Goh CL: Dermatitis from chlorphenesin in a deodorant. Contact Dermatitis 1987; 16:287.
    10) Grant WM & Schuman JSGrant WM & Schuman JS: Toxicology of the Eye, 4th. Charles C Thomas, Springfield, IL, 1993.
    11) Graves AB, White E, & Koepsell TD: The association between aluminum-containing products and Alzheimer's disease. J Clin Epidemiol 1990; 43:35-44.
    12) Guillard O, Fauconneau B, Olichon D, et al: Hyperaluminemia in a woman using an aluminum-containing antiperspirant for 4 years. Am J Med 2004; 117:956-959.
    13) Naradzay J & Barish RA: Approach to ophthalmologic emergencies. Med Clin North Am 2006; 90(2):305-328.
    14) Peate WF: Work-related eye injuries and illnesses. Am Fam Physician 2007; 75(7):1017-1022.
    15) RTECS : Registry of Toxic Effects of Chemical Substances. National Institute for Occupational Safety and Health. Cincinnati, OH (Internet Version). Edition expires July/31/2001; provided by Truven Health Analytics Inc., Greenwood Village, CO.
    16) Shelley WB & Hurley HJ: Anhydrous formation of aluminum chloride for chronic folliculitis. JAMA 1980; 244:1956-1957.
    17) Skelton HG, Smith KJ, & Johnson FB: Zirconium granuloma resulting from an aluminum zirconium complex: a previously unrecognized agent in the development of hypersensitivity granulomas. J Am Acad Dermatol 1993; 28:874-876.
    18) Spoor HJ: Deodorants and antiperspirants. Cutis 1974; 13:180-181.
    19) Sweetman S (Ed): Martindale: The Complete Drug Reference., Micromedex, Inc, Greenwood Village, CO, 2003.